Qianjiang Yongan Pharmaceutical Co Ltd

The company maintains a strong liquidity position, with a current ratio of 5.65, indicating a robust ability to meet short-term obligations. Its liquidity_fpt score suggests that the firm is not under immediate pressure to raise capital, and its free cash flow of 31.87 million CNY supports operational flexibility. However, the company's price-to-earnings ratio of 157.21 is significantly higher than the industry median, suggesting that the market may be pricing in high expectations for future earnings growth.

Profitability metrics show a mixed picture. The company's return on equity (ROE) of 1.13% and return on assets (ROA) of 1.02% are below the industry median, indicating that the company is not generating strong returns relative to its equity and asset base. The gross profit margin of 16.74% is in line with the industry, but the operating margin of 1.34% is below the median, suggesting that the company is facing cost pressures or pricing constraints.

The company's revenue is concentrated in a single geographic market, with all disclosed revenue generated in China. There is no public breakdown of revenue by product segment, but the company's primary business is in pharmaceuticals, with a focus on generic drugs and over-the-counter (OTC) products. This concentration increases exposure to domestic regulatory and economic risks.

The company's growth trajectory is modest. Revenue in the latest reported period was 783.17 million CNY, which is below the analyst estimate of 1.16 billion CNY. The outlook for the current fiscal year suggests a continuation of this trend, with no significant revenue growth expected in the near term. The company's capital expenditure of -62.28 million CNY indicates a reduction in investment, which may signal a focus on cost control rather than expansion.

Risk factors include a medium liquidity risk, as the company has a negative net cash position after subtracting total debt. The dilution risk is low, with no significant dilution expected in the near term. The company has not issued new shares recently, and there is no indication of a pending equity offering or ATM program.

Recent events include the filing of the latest financial report, which shows a decline in revenue and net income compared to prior periods. The company has not issued any material earnings guidance or disclosed any major strategic initiatives in the latest filings.

Qianjiang Yongan Pharmaceutical Co Ltd (002365.SZ) has undergone a formal classification update, with its primary activity now explicitly identified as "Pharmaceuticals" and its economic sector designated as "Healthcare." This structural clarification, marked as a medium-severity change, establishes the foundational context for analyzing the company’s operational focus within the broader healthcare industry. Concurrently, the company’s risk profile has been initialized with specific assessments. Dilution risk is now classified as "low," indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides a baseline for evaluating shareholder equity stability. In contrast, liquidity risk has been assessed as "medium." This designation suggests that while the company maintains operational viability, there may be moderate constraints or variability in its ability to meet short-term financial obligations without significant cost or delay. This metric is critical for understanding the firm's near-term financial flexibility. These updates reflect a comprehensive review of the company’s fundamental attributes rather than a reaction to specific market events or analyst revisions, as no new analyst coverage or index membership changes were recorded. The synthesis of these low-severity risk adjustments and medium-severity taxonomy clarifications offers a more precise framework for future financial analysis of Qianjiang Yongan Pharm.